Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bortezomib + pemetrexed
- Development stage
- Phase 2
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of bortezomib, a proteasome inhibitor, and pemetrexed, an antifolate antineoplastic agent. Bortezomib works by reversibly inhibiting the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells. Pemetrexed inhibits multiple enzymes involved in folate metabolism and DNA synthesis. This combination has been studied primarily for the treatment of non-small-cell lung cancer (NSCLC).
- Brand names
- Alimta (for pemetrexed)Velcade (for bortezomib)
- Other names
- pemetrexed disodium + bortezomib
02
Targets
PSMB5 (Proteasome subunit beta Type-5)DHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on bortezomib + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bortezomib + pemetrexed.